Thirteen stocks in the S&P 500 are targeting 60 percent rises in stock prices...but is it too ambitious? USAToday reports.» Read More
You can get a steady diet of all things ASCO (American Society of Clinical Oncology) on CNBC and here at CNBC.com, so I'm gonna blog about something totally different. Well, it does have to do with cancer prevention. Specifically, staving off cervical cancer and/or the sexually transmitted disease known as HPV, which is the leading cause of cervical cancer.
Next week could be the biggest week for oil and other commodities in years, says Guy Adami. What's the "Word on the Street?"
Appeals courts in New Jersey and Texas on Thursday scrapped verdicts against drug maker Merck stemming from some of the earliest trials involving its once popular painkiller Vioxx.
An experimental osteoporosis drug that is considered to be crucial to the future of biotechnology giant Amgen strengthened bones more than today's most widely-used treatment, research showed.
I'm thinkin' those two drug giants are champin' at the bit for the docs to get McCain off generic Zocor and onto Lipitor or Crestor. On recent conference calls, some PFE officials have said they think a lot of patients who've had a similar experience to McCain's will eventually come back around to Lipitor.
Stocks finished near session lows as oil prices soared and a measure of wholesale inflation surged, sparking worries that the Federal Reserve will start focusing on rising prices rather than slowing growth.
Stocks tumbled Tuesday as oil prices blew past $129 a barrel and a measure of wholesale inflation surged, sparking worries that the Federal Reserve will start focusing on rising prices rather than slowing growth.
There's way too much stuff out of ASCO to do a comprehensive blog entry that would satisfy readers--especially small-cap biotechies. I mean, there are literally thousands of pages of research being published today by analysts on the new data.
Cramer makes the call on viewers' favorite stocks.
The market can swing as much on sentiment as fact. Investors would be wise to remember this.
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
A pair of crucial earnings "beats" capped off a day that defied expectations as the market ended higher despite having every reason to sell off. Find out what happened and how to trade it.
Stocks closed higher as optimism prevailed, even in the face of $122-a-barrel oil. Techs got a boost from speculation that a deal between Microsoft and Yahoo is still possible.
Stocks declined as oil surpassed $122 a barrel and Fannie Mae delivered disappointing results.
After the closing bell yesterday, Merck announced that it plans to get rid of 12-hundred or around 15 percent of its sales reps. Like Schering-Plough, the company is having to adjust to lower sales of its Vytorin and Zetia cholesterol drugs and on top of that the Food and Drug...
Merck, whose earnings have been hurt by patent expirations and declining sales of its Vytorin cholesterol fighter, said Monday it will eliminate another 1,200 members of its U.S. sales force as part of a restructuring begun in late 2005.
Financial pain and physical pain may be linked: A new study says people who make less money and work in blue-collar jobs are more prone to be in pain.
I didn't post yesterday because I was in Philadelphia shooting a story for an upcoming episode of "The Business of Innovation" on CNBC. It's a piece about big pharma and we went to Philly to interview the still very busy former CEO of Merck (two CEOs ago), Dr. Roy Vagelos.
It's a booyah-free zone. There goes Swifty!
Merck says it has received a warning letter from the Food and Drug Administration over concerns at one of its major vaccine manufacturing plants.